NCT00048126View on ClinicalTrials.gov

A Study of Xeloda (Capecitabine) in Patients With Advanced and/or Metastatic Colorectal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

July 31, 2001

Primary Completion Date

January 31, 2005

Study Completion Date

January 31, 2005

Conditions
Colorectal Cancer
Interventions
DRUG

Irinotecan

100mg/m2 iv on days 1, 8, 15 and 22 of each 6 week cycle.

DRUG

capecitabine [Xeloda]

1000mg po bid

Trial Locations (10)

10028

New York

33176

Miami

35216

Hoover

38120

Memphis

87102

Albuquerque

92037-1030

La Jolla

02120

Boston

28233-3549

Charlotte

02908

Providence

37203-1632

Nashville

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT00048126 - A Study of Xeloda (Capecitabine) in Patients With Advanced and/or Metastatic Colorectal Cancer | Biotech Hunter | Biotech Hunter